Abstract Genetic variation in the androgen-to-estrogen conversion pathway has been shown to be associated with risk of breast cancer and, in particular, with estrogen receptor (ER) positive tumours. We aimed at studying how the genetic alterations, which have been identified for risk, are associated with breast cancer prognosticators, with a prior hypothesis that, in general, hormone-related breast cancers have a better prognosis than non-hormone-related breast cancers. Association between tagging SNPs in genes involved in estrogen metabolism and patient's lymph node status, tumour size and histological grade were estimated in a sample of 1569 Swedish breast cancer patients. Polymorphisms in CYP19A1, which have previously been linked to breast cancer risk, are shown to be associated with breast cancer prognosticators. The strongest association was observed for rs4646, with histological grade. The common allele of rs4646, which has been associated with increased breast cancer risk, was associated with lowhistological grade and small tumour size (P = 0.001 and 0.015; 1-sided, respectively). We also found evidence that SNP rs7167936 is associated with histological grade and tumour size (P = 0.010 and 0.005; 1-sided, respectively). We show that rs4646 and rs7167936 are associated with histological grade even amongst only ER-positive tumours (P = 0.008 and 0.011; 1-sided, respectively). Our results provide new evidence that CYP19A1 is involved in both breast cancer risk and prognosis.
Introduction
Exposure to estrogen is an important determinant of the risk of breast cancer. Breast cancer is believed to be induced by excessive estrogen exposure, and genetic variation in genes involved in the estrogen metabolism pathway is therefore likely to be important for the disease. Numerous genetic association studies addressing association with cancer risk and genes in the estrogen metabolism pathway have been reported with conflicting results, probably reflecting the low penetrance of mutations in genes within the estrogen metabolism pathway, suboptimal study designs, underpowered studies or a combination of these factors [1] [2] [3] . We have recently been able to show, using a pathway approach, that there is an association between breast cancer risk and some of the genes involved in the androgen-to-estrogen conversion pathway (a subpathway of the complete estrogen metabolism pathway), particularly for the risk of estrogen receptor (ER)-positive tumours [4] . Gene-based analysis indicated that CYP19A1 was the major contributor to the observed association.
CYP19A1 is located on chromosome 15q21.1 in humans and encodes the aromatase enzyme, which catalyzes the last step of estrogen biosynthesis from androgens. Mutations in CYP19A1 can result in increased or decreased aromatase activity, and it has been suggested that estrogen functions not only as a sex steroid hormone but also plays a part in cell growth or differentiation [5, 6] .
In the current study, we investigated whether the top risk SNPs within the androgen-to-estrogen conversion subpathway, according to [4] , are associated with breast cancer prognosticators; tumour grade, size and lymph node status. Prior to analysis, we hypothesised that alleles associated with an increased risk of breast cancer are associated with good prognosis (and vice versa) since hormone-related breast cancers, identified in terms of menopausal hormone treatment, have also been reported to be associated with favourable prognosis [7] . We assessed association overall and within subgroups of patients stratified by ER-status.
Materials and methods

Study subjects
A Swedish case-control study was initiated in the early 1990s to examine the effect of menopausal hormone use on breast cancer risk. The nation-wide case-control study encompassed all Swedish born women between 50 and 74 years of age and resident in Sweden between October 1993 and March 1995 and diagnosed with breast cancer. The cancer patients were identified through the regional cancer registries in Sweden. Women with previous cancers were excluded to minimise the risk of including patients with a metastasis in the study. Controls were randomly chosen from the Swedish Registry of Total Population and frequency matched to cases, on age. Characteristics of the participants in the breast cancer case-control study have been described elsewhere [4, 7, 8] . For cancer patients, information on tumour characteristics was collected from patient records from surgical and oncological units throughout Sweden. This included estrogen and progesterone receptor expression, histopathological subtype, disease stage according to tumour size and spread to regional lymph nodes. Tumour samples were not assessed for HER2 status or S-phase. The Bloom-Richardson scale or Nottingham histological grade were used as grading systems for classifying grade [7] . From the original case-control study, consisting of 3,345 cases and 3,454 controls, 1,569 breast cancer cases and 1,730 healthy controls were included in a genetic study. Written informed consent was obtained from all the participating subjects, and the study was approved by the Institutional Review Boards in Sweden and the National University of Singapore [4] .
Gene and haplotype tagging SNP selection
The SNPs/genes within the androgen-to-estrogen conversion pathway, which are included in the current study, represent a subset of SNPs/genes from a parent study of the entire estrogen metabolism pathway [4] . Genetic variation in the androgen-to-estrogen conversion (sub-) pathway was shown to be associated with breast cancer risk. In the parent study [4] , gene selections were based on the criteria that the gene should code for an enzyme that contributes to estradiol and estrone metabolism. In total, 35 genes were selected and a two-stage genotyping design was used. In the first stage, 1,007 single nucleotide polymorphisms (SNPs) were selected within the 35 genes and their 30 kb flanking sequences, aiming for a marker density of at least one SNP per 5 kb. Linkage disequilibrium (LD) patterns in these genes were determined using DNA samples from 92 Swedish control women. Haplotypes were reconstructed using the PLEM algorithm implemented in the tagSNP program [9, 10] . TagSNP selection was based on the R 2 coefficient. We chose tagSNPs so that common SNP genotypes (minor allele frequency C0.03) and common haplotypes (frequency C0.03) were predicted with a good coverage of R 2 values C0.8. Overall 302 tagSNPs were selected across 35 genes, and these tagSNPs, in stage 2 of the procedure, were genotyped in all available DNA samples from cases and controls. Of these, 252 tagSNPs were successfully genotyped, from which a further 13 SNPs were excluded on the basis of failing a Hardy-Weinberg equilibrium test, or having a call rate \0.85, or a minor allele frequency \0.01. This left a final set of 239 SNPs distributed among 34 genes, all of which were genotyped. Of these 34 genes, 15 genes (including 120 tagSNPs) are involved in androgen-to-estrogen conversion. We recently showed that there is an association between breast cancer risk and some of the tagSNPs in these 15 genes [4] .
Benjamini and Hochberg [11] introduced an important concept for multiple comparisons that they called the false discovery rate (FDR). The FDR is the expected proportion of false positives among all tests declared significant. In the current study, the FDR q value [11] [12] [13] was estimated for each of the 120 tagSNPs in [4] . The q value is the FDR equivalent of the P value; the q value of an individual test measures the minimum false discovery rate that is incurred when calling that test significant. Out of the 120 tagSNPs, 13 had a false discovery rate q value less than 0.20 (with q values ranging from 0.04 to 0.19); see Table 1 . These 13 tagSNPs were included in the present study and examined for association with breast cancer prognosticators. For an overview of the design of the current study, see Fig. 1 . We note that 6 of the 13 tagSNPs are in CYP19A1.
Prognosticators for breast cancer
The most commonly used prognosticators for breast cancer are TNM stage, histological grade, ER status and S-phase [14] . In the current study, we decided to include the component variables of TNM stage, lymph node status and tumour size, along with histological grade. We did not include ER status since we have already established, in our study material, that the top risk SNPs, in genes involved in androgen-to-estrogen conversion, in particular, increase the risk of ER-positive breast cancer [4] . S-phase could not be included because it was not measured for patients in our study. The lymph node status is either 1 (if there are no nodes affected), 2 (if up to 3 glands are affected) or 3 (if more than 3 glands are affected). Similarly, the tumour grade is scored as either 1 (for a grade I, less aggressive appearance), 2 (for a grade II, intermediate appearance) or 3 (for a grade III, more aggressive appearance).
Statistical analysis
For assessing association between the prognosticators, lymph node status, tumour size and histological grade, and the (13) tagSNPs selected in the present study, we based analysis on all cases with available data (case only analysis). Ordinal (proportional odds) regression was used to model the relationship between ordinal outcome variables (grade and lymph node status) with SNP covariates. Linear regression was used to model the relationship between continuous variables (tumour size) with covariates of interest. Tumour size (in cm) was logarithm transformed to obtain an approximately normally distributed dependent variable. Because of our hypothesis that alleles associated with increased risk of breast cancer are associated with good prognosis (and vice versa), we performed 1-sided hypothesis tests-for each SNP, the alternative hypothesis being that the high risk allele (from [4] ) is associated with a favourable prognosticator value (low grade/low lymph node status/small tumour). We, however, also present P values for 2-sided tests since these are more conservative/standard. We applied Bonferroni corrections to address multiple testing (39 tests of association). Overall (global) evidence of association between the (13) genetic variants and each of the prognosticators was evaluated using the Admixture Maximum Likelihood (AML) method, which is described in detail in Tyrer et al. [15] . This test assesses the experiment-wise significance by examining the empirical distribution of single marker test statistics, to determine whether there exists a cumulative effect from multiple variants. For these analyses, we dichotomised the prognosticators (grades 1 & 2 vs. 3, lymph node status 1 vs. 2 & 3, tumour size B20 vs. [20 mm), since the AML test is for dichotomised outcomes. The AML analysis was performed using software obtained from the authors of [15] . All other statistical analyses were performed using the free statistical software R [16] .
Results
In Table 2 , we present summary statistics for the prognosticators, for the entire case-series, as well as for the subset of cases know to be ER positive. Only just over onehalf of the cases have tumour ER status recorded. Of these, approximately three quarters are ER-positive.
In order to summarise the genetic association with tumour phenotypes in cases overall, we used the AML approach [15] with categorised prognosticators as outcome. We carried out three AML tests of association, in order to assess the cumulative association between the 13 tagSNPs and each of the prognosticators, using all cases. The (2-sided) P values were 0.038, 0.549 and 0.691, for histological grade, tumour size and lymph node status, respectively. Indicating there is a cumulative effect from (some of) the 13 markers included in this study with tumour grade.
To investigate our hypothesis, that the most important genetic variants for breast cancer risk, in genes involved in androgen-to-estrogen conversion, are associated with breast cancer prognosticators, we fitted regression models to grade (ordinal), lymph node status (ordinal) and tumour size (linear). Results are displayed in Table 3 . The lowest P values for association were obtained between histological grade and rs7167936 (P = 0.010 and 0.020 for 1-sided and 2-sided tests, respectively) and rs4646 (P = 0.001 and 0.002 for 1-sided and 2-sided tests, respectively). Markers rs7167936 (P = 0.005, 1-sided) and rs4646 (P = 0.015, 1-sided) also showed association with tumour size (Table 3) . None of the selected markers showed association with lymph node status, coded either as an ordinal variable or as a dichotomized variable. All regression coefficients with a corresponding 2-sided P value \0.05, for tagSNPs in CYP19A1, were such that the high risk allele is associated with less aggressive tumours (the 1-sided P values were less than the 2-sided P values). The 1-sided P value for the association between rs4646 and histological grade remains significant (at a = 0.05) after a (conservative) Bonferroni correction for multiple testing (P = 0.039), although the 2-sided P value does not.
We found that the association between the ''top'' SNPs in CYP19A1 and histological grade remained even when including only cases which are ER-positive (data not shown). For SNPs rs7167936 and rs4646 1-sided P values of 0.011 and 0.008, respectively, were obtained, with regression coefficients 0.27 and 0.31, corresponding to odds ratios of 1.31 and 1.36. Neither marker remained associated for cases that are ER-negative.
Discussion
We have recently shown an association between breast cancer risk and some of the genes involved in the androgento-estrogen conversion pathway [4] . Gene-based analysis indicated that the aromatase gene CYP19A1 was a major contributor to the observed genetic association. In the current study, we hypothesized that genetic variation in the top risk genes, within the androgen-to-estrogen conversion pathway, is also associated with breast cancer prognosis. In our study material, cancers occurring among women treated with menopausal hormones on average have a more favourable prognosis [7] . Following this line of reasoning, we hypothesised that high risk alleles of polymorphisms of genes in the androgen-to-estrogen conversion pathway are, more specifically, associated with breast cancer prognosticators.
The prognosticator with the strongest association was histological grade. Of the 13 studied markers, in the androgen-to-estrogen conversion pathway, the lowest P values for association with histological grade were obtained for rs7167936 and rs4646 (1-sided P values of 0.010 and 0.001), both in CYP19A1.
If genetic variation in the androgen-to-estrogen conversion pathway is primarily associated with ER-positive breast cancer, as we have earlier suggested [4] , this will partially explain the association between risk polymorphisms and the prognosticators. This claim, made in [4] , was made on the basis that MAFs of ''risk-associated'' SNPs were similar in controls and ER-negative breast cancers, but differed in ER-positive cancers. Only in a few cases were there statistically significant differences between MAFs in ER-negative and ER-positive cases (e.g. for rs7167936, P = 0.041). It appears that the level of association we observed between grade and SNPs in CYP19A1 exceeds that which we would expect due solely to MAF differences in ER-positive and ER-negative cancers.
Multiple studies have shown independent prognostic significance of histological grade in breast cancer. To examine the prognostic value of histological grade Rakha et al. [17] investigated the association of grade in patients with operable breast cancer with different tumour size and lymph node subgroups. Multivariate analysis revealed that tumour grade was a significant independent predictor of breast cancer specific survival, with a hazard ratio of 3.9 for grade 3 relative to grade 1 after a median of 9 years, with significant difference in survival for higher histological grade and poorer patient's outcome. Histological grade together with lymph node status and tumour size are the three strongest prognostic determinants for breast cancer.
Assessment of degree of biological aggressiveness of a tumour is crucial as biologically more aggressive tumours are likely to increase in size in a short time, in contrast to less aggressive tumours which exhibit more restricted growth rate. Many breast tumours are estrogen sensitive; estrogen helps them to grow. Aromatase is involved in the production of estrogens, and altered expression of it may be associated with prognosis. The single-nucleotide polymorphism rs4646, of CYP19A1, has been reported to be associated with HER2 status of the tumour [18] and circulating steroid hormones [3] , making it biologically possible that polymorphisms in CYP19A1 may be associated with response to aromatase inhibitors. To examine this hypothesis Garcia-Casado et al. [19] analysed polymorphisms in CYP19A1 in a series of postmenopausal woman treated with neoadjuvant letrozole and described their association with response to treatment and with progression free survival. The minor genetic variant of rs4646 was shown to be associated with poor response to letrozole, and presented a lower progression-free survival, concluding that analysis of rs4646 could improve the clinical management of breast cancer patients. Our result is in agreement with the result presented by Garcia-Casado et al. [19] , since we found the minor variant of this SNP to be associated with high tumour grade.
Strengths of the present study include a large sample size, extensive coverage of SNPs in genes in the androgento-estrogen conversion sub-pathway and a well defined hypothesis-by building on a comprehensive study of breast cancer risk we were able to focus our analysis of breast cancer prognosticators on a small number of polymorphisms (see Fig. 1 ). A limitation of the present work is that several women included in the study had incomplete data on tumour characteristics.
In summary, we found that the polymorphism rs4646 in the 3 0 -untranslated region of CYP19A1 is associated with histological grade and tumour size in postmenopausal women. This supports the hypothesis that analysis of rs4646 could improve the clinical management of postmenopausal breast cancer patients. Further studies based on larger data series are needed to confirm our findings.
